3.7. Adverse Events
gastrointestinal reactions, nausea, vomiting, constipation, dizziness, GI TEAEs, TEAE
ADVERSE EVENTS, LOSS OF APPETITE
Neither fatalities nor severe adverse events happened during the research. The adverse event-related discontinuation rate was 2.94% (2/68) in both groups. Two participants developed gastrointestinal reactions within the first week of starting dulaglutide injection; therefore, they were unwilling to continue to dulaglutide treatment and withdrew from the trial. Approximately 37.14% of the participants with dulaglutide treatment reported at least one gastrointestinal (GI) treatment-emergent adverse event (TEAE); the most common GI TEAEs were nausea (22.86%), vomiting (20.00%), constipation (11.43%), and loss of appetite (11.43%). Generally, most GI TEAEs were mild to moderate in severity, and most were more pronounced within the first 2 weeks, and then gradually ameliorated within 1 month. Approximately 9.09% of the participants who received the CRD regimen alone reported sensations of hunger, and 3.03% of participants reported sensations of dizziness (